Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study.

MLA

Foley, Peter, et al. “Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study.” Dermatology & Therapy, vol. 12, no. 2, Feb. 2022, pp. 511–27. EBSCOhost, https://doi.org/10.1007/s13555-021-00675-w.

APA

Foley, P., Tsai, T.-F., Rodins, K., Hamadah, I. R., Ammoury, A., Dayem, H. A., Abdallah, M., Crowe, S., Haas, S., Pournara, E., Jagiello, P., & Huang, Y.-H. (2022). Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study. Dermatology & Therapy, 12(2), 511–527. https://doi.org/10.1007/s13555-021-00675-w

Chicago

Foley, Peter, Tsen-Fang Tsai, Karl Rodins, Issam Ribhi Hamadah, Alfred Ammoury, Hussein Abdel Dayem, Mahmoud Abdallah, et al. 2022. “Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study.” Dermatology & Therapy 12 (2): 511–27. doi:10.1007/s13555-021-00675-w.